Custom Page

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed ac nisi aliquet, pretium turpis pretium, ullamcorper nisl. Etiam vehicula eu ligula et vestibulum. Morbi nec pulvinar odio. Cras eleifend libero vestibulum augue tempus placerat. Praesent sed libero blandit, molestie dui vitae, luctus lacus. Nulla at nisl pulvinar, pellentesque nisl vel, ultricies ante. In elementum mattis finibus.

Vivamus non lorem a massa semper sagittis. Donec commodo lorem at vulputate ultrices. Duis iaculis ultricies elementum. Integer maximus sed tellus non molestie. Proin id ultricies nibh. Curabitur fermentum, ante in ornare malesuada, odio justo tristique elit, nec consequat ante leo in quam. Morbi id sodales quam. Phasellus pretium placerat risus, eget finibus augue mollis non. Donec sit amet nibh semper, dignissim eros quis, sollicitudin orci. Aenean molestie, risus sit amet porta placerat, sem sapien bibendum lectus, vel pharetra ipsum erat pulvinar elit.

Phasellus faucibus diam sed nisi facilisis facilisis. Curabitur blandit lectus odio, et posuere diam molestie sit amet. Quisque enim arcu, dignissim in leo sed, maximus pellentesque ipsum. Vestibulum placerat tempus erat, ac posuere nisi dignissim non. Fusce eleifend viverra ante, vel accumsan massa lobortis id. Interdum et malesuada fames ac ante ipsum primis in faucibus. Etiam elementum, dolor vitae tincidunt auctor, purus felis viverra tortor, non rhoncus tellus lectus non enim.

Nunc eleifend diam est, nec tincidunt sem molestie at. Maecenas condimentum congue ante ac sollicitudin. Integer aliquet porttitor massa a malesuada. Sed in mauris vulputate, malesuada odio nec, pharetra diam. Vestibulum et nisl venenatis, vehicula nisl ut, tempus lectus. Sed eget scelerisque felis, id tincidunt nibh. Integer semper semper nunc, et condimentum sem dignissim ac. Donec fringilla enim rhoncus ex bibendum condimentum. Duis tincidunt ex vitae est luctus fermentum. In leo ex, tempus et imperdiet nec, consequat a risus.

  • Rare cancer patients and researchers are in serious need of support.
    Scroll down to learn why.

Insufficient funding for rare cancer research leaves patients with very few, if any, treatment options.

Cost VS. Benefits:

Developing treatments for rare diseases—affecting fewer than 200,000 Americans—is not financially viable for most pharmaceutical companies.1

Due to the lack of funding, researchers lack basic tools needed to make progress—in many cases patients are treated with therapies designed for other cancers.

  • Top Three NCI Funded Cancers
  •  
  • Esophageal Cancer
  •  

Example:

In 2012, the top three cancers funded by the National Cancer Institute received $1.2 billion in funding, while esophageal cancer received 2% of that amount.2

Of the top 8 deadliest cancers, 7 are rare.
Deadly cancers have a 5 year survival rate under 50%.
In many cases, survival rates are significantly lower.3

  • New Cases
  • Deaths

Example:

The National Cancer Institute estimates there will be 18,170 new cases of esophageal cancer and 15,450 deaths in 2014 alone.4

TargetCancer Foundation is changing the outlook for those fighting rare cancers by funding innovative rare cancer research, fostering collaborations between researchers, and raising awareness.

Here's how you can join us in making an impact:

We’re partnering with leading researchers to make a real impact
Learn More